Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines

Transplantation

Volumn 65, Issue 9, 1998, Pages 1248-1255

  Beatty, P Robert ^a   Krams, Sheri M ^a   Esquivel, Carlos O ^a   Martinez, Olivia M ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; TACROLIMUS;

ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; DRUG EFFECT; EPSTEIN BARR VIRUS; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; LYMPHOCYTE TRANSFORMATION; PRIORITY JOURNAL;

ANTIGENS, CD95; B-LYMPHOCYTES; CELL DIVISION; CELL LINE, TRANSFORMED; CELL SURVIVAL; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; TACROLIMUS; TUMOR VIRUS INFECTIONS; VIRUS ACTIVATION;

EID: 0032525063     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199805150-00017     Document Type: Article

References (32)

1. Penn I. Epstein-Barr virus associated disorders in transplant patients. Clin Transplant 1992; 6: 214.
2. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23: 1473.
3. Markin RS, Wood RP, Shaw B, Brichacek B, Purtilo D. Immunohistologic identification of Epstein-Barr virus-induced hepatitis reaction after OKT3 therapy following orthotopic liver transplant. Am J Gastroenterol 1990; 85: 1014.
4. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 1991; 23; 1477.
5. Reding R, Wallemacq PE, Lamy ME, et al. Conversion from cyclosporine to FK506 salvage of immunocompromised pediatric liver allografts. Transplantation 1991; 57: 93.
6. Burman K, Crawford DH. Effect of FK506 on Epstein-Barr virus specific cytotoxic T cells. Lancet 1991; 337: 297.
7. Berger R, Meingassner JG, Knapp W. In-vitro effects of cyclosporin A on human B-cell responses. Scand J Immunol 1983; 17: 241.
8. Klaus GGB. Cyclosporine-sensitive and cyclosporine-insensitive modes of B cell stimulation. Transplantation 1988; 46: 11S.
9. Muraguchi A, Butler JL, Kehrl JH, Falkoff RJM, Fauci AS. Selective suppression of an early step in human B cell activation by cyclosporin A. J Exp Med 1983; 158: 690.
10. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 803.
11. Venkataraman L, Francis DA, Wang Z, Liu J, Rothstein TL, Sen R. Cyclosporin-A sensitive induction of NF-AT in murine B cells. Immunity 1994; 1: 189.
12. Goldfeld AE, Flemington EK, Boussiotis VA, et al. Transcription of the tumor necrosis factor a gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells. Proc Natl Acad Sci USA 1992; 89: 12198.
13. Goldfeld AE, Liu P, Liu S, Flemington EK, Strominger JL, Speck SH. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin. Virology 1995; 209: 225.
14. Bonnefoy-Berard N, Genestier L, Flacher M, Revillard JP. The phosphoprotein phosphatase calcineurin controls calcium-dependent apoptosis in B cell lines. Eur J Immunol 1994; 24: 325.
15. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 1997; 158: 4045.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation cytotoxicity assay. J Immunol Methods 1983; 139: 365.
17. Durandy A, Brousse N, Rozenberg F, Basile GDS, Fischer AM, Fischer A. Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies. J Clin Invest 1992; 90: 945.
18. Durandy A, Emilie D, Peuchmaur M, et al. Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice. J Immunol 1994; 152: 5361.
19. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449.
20. Sieg S, Huang Y, Kaplan D. Viral regulation of CD95 expression and apoptosis in T lymphocytes. J Immunol 1997; 159: 1192.
21. Nakamoto Y, Guidotti LG, Pasquetto V, Schreiber RD, Chisari FV. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997; 158: 5692.
22. Ando K, Hiroishi K, Kaneko T, et al. Perform, Fas/Fas ligand, and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997; 158: 5283.
23. Starzl TE, Nalesnik MA, Porter KA, et al. Reversability of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 8377: 583.
24. Ho S, Clipstone N, Timmerman L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80(3): S40.
25. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
26. Kay JE, Smith MC, Frost V, Morgan GY. Hypersensitivity to rapamycin of BJAB B lymphoblastoid cells. Immunology 1996; 87: 390.
27. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death. Transplantation 1995; 60(3): 264.
28. Genestier L, Dearden-Badet MT, Bonnefoy-Berard N, Lizard G, Revillard JP. Cyclosporin A and FK506 inhibit activation-induced cell death in the murine WEHI-231 B cell line. Cell Immunol 1994; 155: 283.
29. Mosialos G, Birkenbach M, Yaiamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389.
30. Rowe M, Peng-Pilon M, Huen DS, et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B cell specific response that is delayed relative to NF-kB activation and to induction of cell surface markers. J Virol 1994; 68(9): 5602.
31. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression: BCL-2 regukates NFAT-mediated activation. Proc Natl Acad Sci USA 1996; 93: 9545.
32. Shibasaki F, Kondo E, Akagi T, McKeon F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997; 386: 728.